Twentyeight-Seven Therapeutics

High-Level Overview

Twentyeight-Seven Therapeutics (28-7) is a stealth biotechnology startup developing small-molecule drugs that modulate non-coding RNA (ncRNA) functions, particularly microRNAs (miRNAs), to treat cancer and other human diseases.[1][2][3] The company targets RNA modulating proteins (RMPs) and RNA-binding proteins to control oncogene expression, suppress mRNA translation, and promote mRNA decay, addressing cancer initiation, progression, and metastasis.[2][4] It serves patients with hard-to-treat cancers by creating a novel class of therapies beyond traditional protein-targeting drugs, with early-stage operations including a pipeline in R&D and a team of 11-50 employees generating under $1M in annual revenue.[2]

Founded as a Delaware C-Corp in 2016, 28-7 emerged from academic expertise in RNA biology and has since attracted investment from Sofinnova Partners, reflecting growing momentum in RNA therapeutics.[2][3]

Origin Story

Twentyeight-Seven Therapeutics was established on April 7, 2016, in Delaware as a C-Corp, with its principal operations in Watertown, MA, and a registered agent in Cambridge, MA.[2] The core technology stems from four founding scientists—leading researchers in RNA biology and cancer—who developed approaches to modulate short ncRNAs like miRNAs that regulate gene expression.[2][3] This idea emerged from insights into ncRNA's role in disease, positioning 28-7 as an early pioneer in targeting these undruggable elements with small molecules.[1][2] Early traction included building a full executive team, R&D pipeline, and website, while operating in stealth mode before gaining visibility through biotech networks.[2]

Core Differentiators

• Novel RNA Modulation Platform: Unlike conventional drugs targeting proteins directly, 28-7 develops small molecules that modulate ncRNA levels by interacting with RNA-binding proteins and RMPs, enabling control over oncogenes involved in multiple cancer hallmarks.[1][2][4]
• Focus on Undruggable Targets: Specializes in miRNAs that inhibit gene expression via mRNA decay and translation suppression, opening new avenues for cancers resistant to existing therapies.[2]
• Academic-to-Industry Translation: Leverages foundational science from four RNA/cancer experts, combined with a compact team (11-50) for agile development in biotechnology and drug discovery.[2][3]
• Investor-Backed Pipeline: Supported by Sofinnova Partners' early-stage capital strategy, providing resources for groundbreaking biopharma innovation.[3]

Role in the Broader Tech Landscape

Twentyeight-Seven rides the RNA therapeutics wave, accelerated by mRNA vaccine successes and advances in CRISPR/RNA editing, shifting focus from protein-centric drugs to the "dark matter" of the genome—ncRNAs regulating 98% of transcribed human DNA.[1][2][4] Timing aligns with surging demand for precision oncology, as cancers evolve resistance to immunotherapies and kinase inhibitors, making RNA modulation a timely market force amid a $100B+ oncology sector.[2] By influencing the biotech ecosystem, 28-7 contributes to Sofinnova's portfolio of disruptive biopharma startups, fostering innovation in RNA drug discovery and potentially reshaping treatment paradigms for metastatic diseases.[3]

Quick Take & Future Outlook

Recently rebranded to Redona Therapeutics, 28-7 is poised for clinical advancement, likely advancing its miRNA-modulating pipeline into trials amid booming RNA biotech funding.[3] Trends like AI-driven target identification and small-molecule RNA stabilizers will propel its growth, potentially expanding beyond cancer to fibrosis or neurodegeneration. Its influence may evolve from stealth innovator to ecosystem leader, delivering first-in-class therapies that tie back to its founding mission: revolutionizing drug discovery through ncRNA control.[2][3]